Immediate Impact
63 standout
Citing Papers
Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment
2025 Standout
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Works of Danfeng Dong being referenced
α‐Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades
2019
Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Danfeng Dong | 95 | 100 | 24 | 59 | 20 | 242 | |
| Saveria Mazzara | 51 | 97 | 17 | 36 | 17 | 221 | |
| Hailing Yao | 81 | 100 | 24 | 26 | 22 | 242 | |
| Shunfang Liu | 58 | 174 | 36 | 95 | 24 | 272 | |
| Yuhua Chen | 34 | 106 | 16 | 43 | 24 | 267 | |
| Ida Russo | 44 | 146 | 71 | 95 | 21 | 274 | |
| L Y Pan | 68 | 139 | 22 | 20 | 17 | 286 | |
| Lijuan Bian | 49 | 150 | 38 | 126 | 18 | 297 | |
| Ganjun Kang | 74 | 101 | 63 | 48 | 21 | 283 | |
| Yuqing Miao | 52 | 66 | 17 | 39 | 22 | 213 | |
| Yu-Chu Wang | 94 | 114 | 21 | 25 | 14 | 285 |
All Works
Login with ORCID to disown or claim papers
Loading papers...